Although the randomized controlled clinical trial of primary thrombosis prevention in asymptomatic, persistently aPL-positive individual without the definite APS has been conducted, these individuals do not benefit from aspirin for primary thrombosis prophylaxis [19]. Here, FASLG is linked to autoimmune polyendocrinopathy.